1. Generics Bulletin
  2. >>Products

MSN’s Novadoz Makes Multiple US Launches

Company Commences Shipping Of Albendazole, Droxidopa, Deferasirox And Pregabalin

 
• By Akriti Seth

India’s MSN Labs has kicked off the year by launching four recently-approved generics in the US through affiliate Novadoz, including albendazole, droxidopa, deferasirox and pregabalin. The company says it is preparing a “deep pipeline” of launches for the next 10 years.

launches
Four launches have followed FDA approvals • Source: Alamy

India’s MSN Laboratories Pvt. Ltd. has kicked off 2021 by launching four generics after receiving a raft of US Food and Drug Administration approvals during the first quarter. Through its US affiliate, Novadoz, the company has launched albendazole 200mg tablets; droxidopa 100mg, 200mg, 300mg capsules; deferasirox granules in 180mg and 360mg sachets; and pregabalin extended-release tablets in 82.5mg, 165mg and 330mg strengths.

Benefiting from the vertical integration of MSN’s manufacturing of active pharmaceutical ingredients, key starting materials and product intermediates, the company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

Formycon Snatches First Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Lupin Concedes To Wakix IP With 2030 Launch Date Agreement

 
• By Dean Rudge

Ahead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By Dean Rudge

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.

More from Generics Bulletin

Patent Settlements Are ‘Critically Necessary’ As AAM Calculates $423bn Savings Since 2013

 
• By Urtė Fultinavičiūtė

The US healthcare system saved billions by allowing early market entry for generic and biosimilar medicines through patent settlements. However, long-winded litigations with an expensive price tag and the Senate’s reintroduced pay-for-delay bill are set to make the situation even more dire.

US ‘Red Tape’ Bill Again Targets Biosimilar Interchangeability – Will It Succeed This Time?

 
• By Dave Wallace

After multiple past attempts, US legislators have once again proposed a bill that would make all biosimilars immediately interchangeable upon approval. Could a fresh political context help it to succeed this time?

AstraZeneca Agrees Last-Minute $50m Settlement In Seroquel XR Delay Case

 
• By Dean Rudge

A class action suit alleging AstraZeneca delayed generic competition for Seroquel XR by making illegal agreements that stifled market entry for generic quetiapine competitors has been dismissed after the originator agreed to settle for tens of millions of dollars.